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Background/Objectives: Atopic dermatitis (AD) is the most prevalent inflammatory skin 
disorder, and is often associated with a personal or family history of atopic disease. The 
presence of loss-of-function mutations in the filaggrin gene (FLG) is the main predisposing 
factor for AD. FLG mutations show ethnic and geographical variations, even between European 
populations. We sought to determine the frequency of the 3 most common FLG null mutations 
in a population of Spanish children consisting of healthy controls and AD patients. We also 
investigated the association between these 3 FLG mutations and AD.  
Methods: A total of 214 participants (111 AD patients and 103 healthy controls) were enrolled 
in this study. Genotyping for 3 FLG null mutations (R501X, 2282del4, and R2447X) was 
performed by conventional Sanger sequencing. 
Results: The combined mutation frequency was 1.9% in the control group and 12.6% in the AD 
group. The most common FLG mutation in AD patients was R501X (9.9%), followed by R2447X 
(2.7%) and 2282del4 (1.8%). 
Conclusion: These findings further our understanding of the prevalence of FLG null mutations 
in the Spanish population, and suggest that the frequency of FLG mutations in AD patients in 





Atopic dermatitis (AD) is the most prevalent inflammatory skin disorder, and is often 
associated with a personal or family history of atopic disease, allergic rhinitis, and asth-
ma. Although the pathophysiology of AD remains to be fully elucidated, experts agree 
that a complex relationship between a hyperactive immune system and skin barrier 
dysfunction, together with environmental factors, may underlie the development of 
AD (1).  
 
Filaggrin is an epidermal protein that plays crucial roles in forming and maintaining the 
integrity of the skin barrier. It contributes to the formation of corneocytes, and its 
intracellular metabolites (urocanic acid and pyrrolidone-5-carboxylic acid) are key 
components of the skin’s natural moisturizing factor and are critical for hydration, pH 
maintenance, and UV-B protection (2). Loss-of-function mutations in the filaggrin gene 
(FLG, OMIM 135940) result in reduced or absent levels of filaggrin protein and its 
degradation products (3), and are the primary predisposing factor for AD (4), 
underscoring the role of skin barrier disorders in the pathogenesis of AD. 
 
FLG mutations show ethnic and geographical variations. The global prevalence of FLG 
mutations is greater in European versus Asian populations (7.7% vs 3%) (5, 6), and 
varies considerably among European (2) and Asian (7) populations of AD patients. In 
the United States, the prevalence of FLG mutations varies among the different ethnic 
groups. FLG mutations are 6 times less common in African American than in 
European American patients (5.8% vs 27.5%), even in patients with severe AD (8, 9). 
 
The 3 most frequent FLG null mutations reported in studies of European populations 
are R501X, 2282del4, and R2447X, with prevalences ranging from 7% to 10% (2, 10). 
These mutations are significantly associated with AD (10). There are marked 
differences in the prevalence of FLG mutations detected in northern versus southern 
European populations: in certain northern European populations of AD patients the 
prevalence of FLG mutations ranges from 25–50% (4, 5), while in southern European 
populations FLG mutations are uncommon or even absent, with rates ranging from 
0.5% to 4% (11-14).  
 
Only 1 study has assessed the prevalence of FLG mutations in a Spanish population, 
specifically in a cohort of asthma patients and a corresponding control group (15). That 
study revealed frequencies of 2% and 1% for R501X and 2282del4, respectively, in the 
control group, and lower frequencies in the asthma cohort (1% and absent, 
respectively). In this study, we sought to characterize the prevalence of these null 
mutations in a group of children diagnosed with AD and in a group of healthy controls. 
 
 




We conducted a case-control pilot study of patients aged between 2 months and 14 
years who had current AD at the time of inclusion, skin phototype 2 to 4, 
Mediterranean phenotype, and both parents from Spanish origin. Participants were 
recruited between January 2011 and December 2012 in the Departments of 
Dermatology and Pediatric Allergy of the Hospital San Jorge (Huesca, Spain), primary 
care centers in Huesca city, and the Department of Dermatology of the Hospital Niño 
Jesús (Madrid, Spain). Control subjects were recruited at the University Hospital 
Miguel Servet (Zaragoza, Spain), applying the following exclusion criteria: family history 
of atopy or allergic diseases, symptoms of atopic eczema, asthma or hay fever, food or 
pollen allergies or other environmental allergens (e.g. animals).  
 
AD severity was scored using the scoring atopic dermatitis (SCORAD) index (16, 17), 
and patients classified as mild (SCORAD <15), moderate (SCORAD 15-40), or severe 
(SCORAD >40) (11, 18). Personal history of atopic diseases, including asthma and 
allergic rhinitis, was also recorded. 
 
The study protocol was approved by the Aragon Ethical Committee for Clinical 
Research (PI08/81). Written informed consent was obtained from all participants, or 
their guardians, before inclusion. 
 
Genomic studies  
 
Genomic DNA was obtained from peripheral blood leukocytes extracted from EDTA 
whole blood samples using the QIAamp DNA Blood Mini Kit (QIAGEN, Germany) and an 
automated EZ1 biorobot (QIAGEN, Germany). Genotyping for the FLG mutations 
R501X, 2282del4, and R2447X was performed by PCR fragment amplification followed 
by conventional Sanger sequencing. The primers used were designed based on the 




Descriptive statistics for quantitative values were expressed as the mean and standard 
deviation (SD), in accordance with the data distribution. Frequencies and percentages 
were used to describe categorical variables. Chi-squared or Fisher’s exact tests were 
used to assess associations between FLG mutations and AD, as well as AD-associated 
variables, including SCORAD index and associated atopic diseases. The association of 
genotypes or alleles with AD was assessed by calculating Odds Ratio (OR) and 95% 
confidence intervals. The level of statistical significance was set at p<0.05. Statistical 





Clinical features  
 
Table 1 summarizes the clinical characteristics of the sample. The total number of 
participants enrolled was 214; 111 with a diagnosis of AD and 103 healthy controls 
(mean [SD] age: 5.51 [3.93] and 9.72 [6.22] years, respectively). Based on SCORAD 
index, 20 patients (18%) had mild AD, 70 (63%) had moderate AD, and 21 (19%) had 
severe AD. In the AD group, the frequency of asthma and rhinitis was 30% and 17%, 
respectively. Both conditions were absent in the control group.  
 
The frequency and distribution of FLG mutations R501X, 2282del14, and R2447X and of 
the combined FLG genotype for each group are shown in Table 2. All 3 mutations were 
detected in the AD group, whereas only R501X and 2282del4 were identified in 2 
controls. FLG mutations were detected in 14 AD patients, all of whom were het-
erozygous for 1 of the null mutations, and 2 of whom were compound heterozygous 
carriers of 2 different FLG mutations (see Supplementary Material). Mutations R501X, 
2282del4, and R2447X were carried by 11 (9.9%), 2 (1.8%), and 3 (2.7%) AD patients, 
respectively. The combined frequency of FLG mutations was 1.9% for the control 
population and 12.6% in AD patients. 
 
Analysis of the combination of all 3 FLG mutations of interest revealed a significant 
association with susceptibility to AD (p=0.006). A significant association with AD was 
observed only for the R501X mutation (OR= 11.220, p=0.005) (Table 2).  
 
Although most of the FLG mutations were detected in patients with moderate AD 
(n=11), we found no significant association between AD severity and FLG mutations, 
either individually or combined (Table 3), and no association between FLG null 




This is the first study to evaluate the frequency of the most common FLG loss-of-
function mutations (R501X, 2282del4, and R2447X) in a population of Spanish AD 
patients. The combined frequency revealed a prevalence of 1.9% in the control group 
and 12.6% in AD patients. R501X (9.9%) was the most common FLG mutation in our AD 
cohort, followed by R2447X (2.7%) and 2282del4 (1.8%). These results are similar to 
those reported by Cubero et al. in a population of asthmatic patients from the same 
geographical area (14). Those authors reported frequencies of 2% and 1% for R501X 
and 2282del4, respectively, and, in line with our findings, no association between 
these main FLG null-mutations and asthma.  
 
The frequency of FLG loss-of-function mutations in our healthy control population 
(1.9%) is similar to that reported in previous studies of Mediterranean or southern 
European populations, including Italian (0.6%) (13), Croatian (2.6%) (14), Spanish 
(3.0%) (15), and French (4%) (11) cohorts. However, it is lower than that reported in 
northern European countries, including Germany (7.4%) (19) and England (8.8%)  (20) 
(Table 4).  
 
In our AD cohort, the prevalence of the FLG loss-of-function mutations R501X, 
2282del4, and R2447X (9.9%, 1.8%, and 2.7%, respectively) was significantly lower 
than that reported for the same 3 mutations in AD patients in northern European 
countries, including England (42.3%) (20) and Germany (22.9%) (19, 21). However, 
frequencies similar to those reported here have been reported in AD cohorts in Poland 
(10.3%) (18) and in other Germany studies (11.0%) (22) which reflects the complexity 
of the distribution. The only two published studies of Mediterranean AD cohort 
(French and Italian) reported mutation frequencies similar to (in case of French cohort) 
or slightly lower (in case of Italian cohort), than those reported here (11, 12) (Table 4). 
Our results are not comparable to those reported in the North American population, 
since there are considerable ethnic differences. 
 
Our findings confirm the association between FLG mutations and AD susceptibility: a 
child carrying one of these 3 mutations is more likely to develop AD than one without. 
These results are in agreement with previous reports. 
 
A limitation of our study is the small sample size. A key strength of the study is that it is 
the first such study of AD patients in Spain. One explanation for the low frequency of 
FLG mutations in our cohort is that decreased FLG expression caused by either genetic 
mutations or skin inflammation can induce filaggrin deficiency. This is one potential 
reason why it has not been possible in this study to establish an association with other 
allergic diseases. 
 
In conclusion, our study furthers our understanding of the prevalence of FLG 
mutations in Spanish AD patients, and shows that the frequency of the most common 
FLG null mutations in this cohort is slightly higher than that previously reported in 
other Mediterranean populations. Furthermore, our findings corroborate the 
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